Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2003 | 06-2003 | 03-2003 | 12-2002 | 09-2002 | |
| Sales | 45,405 | 53,977 | 44,939 | 31,516 | 32,076 |
| Cost of Goods | 23,276 | 30,678 | 27,122 | 6,786 | 12,199 |
| Gross Profit | 22,129 | 23,299 | 17,817 | 24,730 | 19,877 |
| Operating Expenses | 9,805 | 11,534 | 11,816 | 10,602 | 5,456 |
| Operating Income | 12,600 | 12,443 | 6,123 | 14,914 | 14,620 |
| Interest Expense | 0 | 0 | 470 | 0 | 0 |
| Other Income | 207 | 377 | 753 | 1,248 | 1,289 |
| Pre-tax Income | 12,807 | 12,820 | 6,406 | 16,162 | 15,909 |
| Income Tax | 4,574 | 4,551 | 2,274 | 5,976 | 5,698 |
| Net Income Continuous | 8,233 | 8,269 | 4,132 | 10,186 | 10,211 |
| Net Income | $8,233 | $8,269 | $4,132 | $10,186 | $10,211 |
| EPS Basic Total Ops | 0.26 | 0.26 | 0.13 | 0.32 | 0.32 |
| EPS Basic Continuous Ops | 0.26 | 0.26 | 0.13 | 0.31 | 0.32 |
| EPS Diluted Total Ops | 0.25 | 0.26 | 0.13 | 0.30 | 0.31 |
| EPS Diluted Continuous Ops | 0.26 | 0.26 | 0.13 | 0.31 | 0.31 |
| EBITDA(a) | $16,167 | $15,452 | $9,365 | $17,129 | $15,913 |